胸膜腔内注射聚桂醇治疗难治性肝性胸水1例报告

李常洲; 李建辉; 郝欣; 姜海斌; 王爱民; 花海洋; 齐静; 张静哲

doi:10.3969/j.issn.1001-5256.2021.09.033

胸膜腔内注射聚桂醇治疗难治性肝性胸水1例报告

DOI: 10.3969/j.issn.1001-5256.2021.09.033

承德市中心医院消化内科，河北承德 067000

基金项目:

2019年度河北省医学科学研究课题计划 (20191297)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：李常洲负责文献检索、资料收集分析及论文撰写；李建辉负责课题设计、论文修改及最后定稿；郝欣、姜海斌、王爱民、花海洋、齐静、张静哲负责文献的搜索、分析和整理。

详细信息

通信作者:
李建辉，changzhou20@126.com

中图分类号: R561
计量
- 文章访问数: 432
- HTML全文浏览量: 84
- PDF下载量: 32
- 被引次数: 0
出版历程
- 收稿日期: 2021-01-22
- 录用日期: 2021-02-15
- 出版日期: 2021-09-20

Treatment of refractory hepatic hydrothorax by intrapleural injection of lauromacrogol: A case report

Department of Gastroenterology, Chengde Central Hospital, Chengde, Hebei 067000, China

Research funding:

Hebei Medical Science Research Project 2019 (20191297)

摘要

- 肝硬化 /
- 胸腔积液 /
- 聚桂醇
- Liver Cirrhosis /
- Pleural Effusion /
- Lauromacrogol

HTML全文

图 1 2017年10月5日胸部CT

注：a, 冠状位；b，横断位(纵隔窗)。右侧大量胸腔积液，局部肺不张。

下载: 全尺寸图片幻灯片

图 2 2017年12月10日胸部CT

注：a，冠状位；b，横断位(肺窗)。右侧大量胸腔积液、右肺不张。

下载: 全尺寸图片幻灯片

图 3 2017年12月15日胸部CT

注：经胸腔引流管充分引流后见胸腔积液已明显减少，右肺复张。

下载: 全尺寸图片幻灯片

图 4 2017年12月22日(术后1周)胸部及腹部CT

注：a，横断位(纵隔窗)；b，横断位(肺窗)；c，腹部CT。仅见右肺叶间裂少量积液，右肺中叶膨胀不好，右肺上下叶均复张较好。

下载: 全尺寸图片幻灯片

图 5 2018年1月24日胸部及腹部CT

注：a，冠状位；b，横断位(纵隔窗)；c，横断位(肺窗)；d，腹部CT。胸腔积液已消失，右肺膨胀良好，同时腹水也明显减少。

下载: 全尺寸图片幻灯片

参考文献(31)

[1]	AL-ZOUBI RK, ABU GHANIMEH M, GOHAR A, et al. Hepatic hydrothorax: Clinical review and update on consensus guidelines[J]. Hosp Pract (1995), 2016, 44(4): 213-223. DOI: 10.1080/21548331.2016.1227685.
[2]	SUÁREZ PM, GILART JL. Pleurodesis in the treatment of pneumothorax and pleural effusion[J]. Monaldi Arch Chest Dis, 2013, 79(2): 81-86. DOI: 10.4081/monaldi.2013.96.
[3]	ZAHID I, ROUTLEDGE T, BILLÈ A, et al. What is the best treatment for malignant pleural effusions?[J]. Interact Cardiovasc Thorac Surg, 2011, 12(5): 818-823. DOI: 10.1510/icvts.2010.254789.
[4]	RODRIGUEZ-PANADERO F, MONTES-WORBOYS A. Mechanisms of pleurodesis[J]. Respiration, 2012, 83(2): 91-98. DOI: 10.1159/000335419.
[5]	AGARWAL R, KHAN A, AGGARWAL AN, et al. Efficacy & safety of iodopovidone pleurodesis: A systematic review & meta-analysis[J]. Indian J Med Res, 2012, 135: 297-304.
[6]	CHAI Y, ZHOU Z, SONG J, et al. Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas[J]. J Dermatol, 2019, 46(9): 770-776. DOI: 10.1111/1346-8138.14992.
[7]	SCHIBLER F, BORRADORI L, RAMELET AA. Subcutaneous injection of large volumes of polidocanol[J]. Dermatol Surg, 2019, 45(3): 476-477. DOI: 10.1097/DSS.0000000000001544.
[8]	TU CY, CHEN CH. Spontaneous bacterial empyema[J]. Curr Opin Pulm Med, 2012, 18(4): 355-358. DOI: 10.1097/MCP.0b013e328352b50f.
[9]	NORVELL JP, SPIVEY JR. Hepatic hydrothorax[J]. Clin Liver Dis, 2014, 18(2): 439-449. DOI: 10.1016/j.cld.2014.01.005.
[10]	WINTER H, DRÄGER E, STERRY W. Sclerotherapy for treatment of hemangiomas[J]. Dermatol Surg, 2000, 26(2): 105-108. DOI: 10.1046/j.1524-4725.2000.98012.x.
[11]	GROVER C, KHURANA A, BHATTACHARYA SN. Sclerotherapy for the treatment of infantile hemangiomas[J]. J Cutan Aesthet Surg, 2012, 5(3): 201-203. DOI: 10.4103/0974-2077.101383.
[12]	TREMBLAY A, STATHER DR, KELLY MM. Effect of repeated administration of low-dose silver nitrate for pleurodesis in a rabbit model[J]. Respirology, 2011, 16(7): 1070-1075. DOI: 10.1111/j.1440-1843.2011.02007.x.
[13]	CHEN Y, LI C, XU L, et al. Novel treatment for chylothorax after esophagectomy with 50% glucose pleurodesis[J]. Ann Vasc Surg, 2010, 24(5): 694. e9-e13. DOI: 10.1016/j.avsg.2009.10.021.
[14]	FUJINO K, MOTOOKA Y, KOGA T, et al. Novel approach to pleurodesis with 50% glucose for air leakage after lung resection or pneumothorax[J]. Surg Today, 2016, 46(5): 599-602. DOI: 10.1007/s00595-015-1223-2.
[15]	ROUSSOS A, PHILIPPOU N, MANTZARIS GJ, et al. Hepatic hydrothorax: Pathophysiology diagnosis and management[J]. J Gastroenterol Hepatol, 2007, 22(9): 1388-1393. DOI: 10.1111/j.1440-1746.2007.05069.x.
[16]	BADILLO R, ROCKEY DC. Hepatic hydrothorax: Clinical features, management, and outcomes in 77 patients and review of the literature[J]. Medicine (Baltimore), 2014, 93(3): 135-142. DOI: 10.1097/MD.0000000000000025.
[17]	KIAFAR C, GILANI N. Hepatic hydrothorax: Current concepts of pathophysiology and treatment options[J]. Ann Hepatol, 2008, 7(4): 313-320. http://www.annalsofhepatology.com/PDF/vol7n4/Hp084-02.pdf
[18]	LIEBERMAN FL, HIDEMURA R, PETERS RL, et al. Pathogenesis and treatment of hydrothorax complicating cirrhosis with ascites[J]. Ann Intern Med, 1966, 64(2): 341-351. DOI: 10.7326/0003-4819-64-2-341.
[19]	YALCIN NG, CHOONG CK, EIZENBERG N. Anatomy and pathophysiology of the pleura and pleural space[J]. Thorac Surg Clin, 2013, 23(1): 1-10. DOI: 10.1016/j.thorsurg.2012.10.008.
[20]	LV Y, HAN G, FAN D. Hepatic hydrothorax[J]. Ann Hepatol, 2018, 17(1): 33-46. DOI: 10.5604/01.3001.0010.7533.
[21]	VILLENA GARRIDO V, CASES VIEDMA E, FERNÁNDEZ VILLAR A, et al. Recommendations of diagnosis and treatment of pleural effusion. Update[J]. Arch Bronconeumol, 2014, 50(6): 235-249. DOI: 10.1016/j.arbres.2014.01.016.
[22]	BORCHARDT J, SMIRNOV A, METCHNIK L, et al. Treating hepatic hydrothorax[J]. BMJ, 2003, 326(7392): 751-752. DOI: 10.1136/bmj.326.7392.751.
[23]	SINGH A, BAJWA A, SHUJAAT A. Evidence-based review of the management of hepatic hydrothorax[J]. Respiration, 2013, 86(2): 155-173. DOI: 10.1159/000346996.
[24]	LEE WJ, KIM HJ, PARK JH, et al. Chemical pleurodesis for the management of refractory hepatic hydrothorax in patients with decompensated liver cirrhosis[J]. Korean J Hepatol, 2011, 17(4): 292-298. DOI: 10.3350/kjhep.2011.17.4.292.
[25]	FELLER-KOPMAN D, LIGHT R. Pleural disease[J]. N Engl J Med, 2018, 378(8): 740-751. DOI: 10.1056/NEJMra1403503.
[26]	WEST JB. Snorkel breathing in the elephant explains the unique anatomy of its pleura[J]. Respir Physiol, 2001, 126(1): 1-8. DOI: 10.1016/s0034-5687(01)00203-1.
[27]	WEST JB. Why doesn't the elephant have a pleural space?[J]. News Physiol Sci, 2002, 17: 47-50. DOI: 10.1152/nips.01374.2001.
[28]	MIERZEJEWSKI M, KORCZYNSKI P, KRENKE R, et al. Chemical pleurodesis - a review of mechanisms involved in pleural space obliteration[J]. Respir Res, 2019, 20(1): 247. DOI: 10.1186/s12931-019-1204-x.
[29]	STRUNK H, MARINOVA M. Transjugular Intrahepatic Portosystemic Shunt (TIPS): Pathophysiologic basics, actual indications and results with review of the literature[J]. Rofo, 2018, 190(8): 701-711. DOI: 10.1055/a-0628-7347.
[30]	DHANASEKARAN R, WEST JK, GONZALES PC, et al. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis[J]. Am J Gastroenterol, 2010, 105(3): 635-641. DOI: 10.1038/ajg.2009.634.
[31]	VIZZUTTI F, SCHEPIS F, ARENA U, et al. Transjugular intrahepatic portosystemic shunt (TIPS): Current indications and strategies to improve the outcomes[J]. Intern Emerg Med, 2020, 15(1): 37-48. DOI: 10.1007/s11739-019-02252-8.